Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Recruiting
Phase 2
Interventional Study
Venous Thromboembolism
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 5,478 (estimated)
- Sponsor
- University of Miami · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* \> 18 years of age
* Planning to undergo a primary total hip or knee arthroplasty
Exclusion Criteria:
* High risk patients for VTE as defined by:
* History of venous thromboembolism
* Active malignancy
* Known pro thrombotic condition
* BMI \> 40
* Patients requiring …
Contacts